Literature DB >> 23606920

Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.

Syreeta L Tilghman1, Gauri Sabnis, Angela M H Brodie.   

Abstract

To investigate the mechanisms by which breast cancer cells adapt and are able to grow during estrogen deprivation, human estrogen receptor-α (ERα)-positive breast cancer cells stably transfected with the aromatase gene (MCF-7Ca) were cultured in steroid-depleted medium for 6-8 months until they started proliferating. Compared with the parental MCF-7Ca cells, long-term estrogen-deprived UMB-1Ca cells exhibited increased aromatase activity (2000%), AIB1 expression (3500%) and ERα expression (100%). When MCF-7Ca cells were isolated from tumors of mice treated for 12 months with an aromatase inhibitor, letrozole, ERα was reduced (50%) whereas AIB1 levels were increased (>1000%), suggesting that the mechanism of estrogen deprivation might predetermine the signaling pathway utilized. To a lesser extent long-term estrogen-deprived MCF-7 cells (LTED) displayed an increase in AIB1, ERα and aromatase activity. Consistent with other findings, the growth of the LTED cells was inhibited by estradiol and antiestrogens, whereas the UMB-1Ca cells were slightly stimulated by estradiol and inhibited by antiestrogens and letrozole. In LTED cells treated with estradiol, levels of AIB1 and ERα (95%) were reduced. Interestingly, estradiol treatment caused no change in AIB1 and ERα expression in the UMB-1Ca cells which might explain the differential growth effect of the cells to estradiol. Together, these results demonstrate that estrogen deprivation results in the upregulation of the estrogen signaling pathway at the level of AIB1, ERα and aromatase, which might attenuate ER-mediated transcription representing one mechanism by which tumors adapt to proliferation in a low estrogenic environment.

Entities:  

Keywords:  aromatase; breast cancer; coactivators; estrogen receptor; long-term estrogen deprivation

Year:  2011        PMID: 23606920      PMCID: PMC3629971          DOI: 10.1515/hmbci.2010.042

Source DB:  PubMed          Journal:  Horm Mol Biol Clin Investig        ISSN: 1868-1883


  17 in total

1.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Authors:  S L Anzick; J Kononen; R L Walker; D O Azorsa; M M Tanner; X Y Guan; G Sauter; O P Kallioniemi; J M Trent; P S Meltzer
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development.

Authors:  J Xu; L Liao; G Ning; H Yoshida-Komiya; C Deng; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

Authors:  Gauri J Sabnis; Danijela Jelovac; Brian Long; Angela Brodie
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

5.  Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.

Authors:  Gernot Hudelist; Klaus Czerwenka; Ernst Kubista; Erika Marton; Kerstin Pischinger; Christian F Singer
Journal:  Breast Cancer Res Treat       Date:  2003-03       Impact factor: 4.872

6.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

7.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

8.  The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

Authors:  Brian J Long; Danijela Jelovac; Apinya Thiantanawat; Angela M Brodie
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

9.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.

Authors:  F Denizot; R Lang
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

10.  Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.

Authors:  S A Oñate; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

View more
  4 in total

1.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

2.  Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.

Authors:  Karen M Gallegos; Jankiben R Patel; Shawn D Llopis; Rashidra R Walker; A Michael Davidson; Wensheng Zhang; Kun Zhang; Syreeta L Tilghman
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

3.  Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Authors:  Patrick P Carriere; Shawn D Llopis; Anna C Naiki; Gina Nguyen; Tina Phan; Mary M Nguyen; Lynez C Preyan; Letitia Yearby; Jamal Pratt; Hope Burks; Ian R Davenport; Thu A Nguyen; KiTani Parker-Lemieux; Florastina Payton-Stewart; Christopher C Williams; Stephen M Boué; Matthew E Burow; Bridgette Collins-Burow; Aaron Hilliard; A Michael Davidson; Syreeta L Tilghman
Journal:  Int J Environ Res Public Health       Date:  2015-12-22       Impact factor: 3.390

4.  The role of amplified in breast cancer 1 in breast cancer: A meta-analysis.

Authors:  Jianjing Hou; Jingting Liu; Mengci Yuan; Chunyan Meng; Jianhua Liao
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.